MegaStudyEdu (215200) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
12 May, 2026Executive summary
Achieved consolidated revenue of KRW 884.9 billion in FY2025, a 6.1% decrease year-over-year, with operating income of KRW 121.0 billion, down 2.1% from the previous year.
Net income surged 85.3% year-over-year to KRW 92.9 billion, mainly due to a low base effect from non-recurring losses in the prior year.
Total assets increased by 2.0% to KRW 896.2 billion, while total liabilities decreased by 8.7% to KRW 375.6 billion.
Equity rose 11.5% to KRW 520.6 billion, driven by higher retained earnings.
Financial highlights
Gross profit was KRW 501.8 billion, down 5.9% year-over-year.
Selling, general, and administrative expenses decreased by 7.2% to KRW 380.3 billion.
Basic and diluted EPS were KRW 8,072, up 92.2% year-over-year.
Cash and cash equivalents at year-end were KRW 66.3 billion, up from KRW 54.4 billion.
Dividend per share increased to KRW 3,000, with a payout ratio of 36.4%.
Outlook and guidance
Management expects continued focus on operational efficiency and cost control.
Strategic divestiture of the underperforming civil service business and acquisition of Unistudy are expected to improve profitability and expand market share in higher education.
Latest events from MegaStudyEdu
- Q1 2025 operating profit rose 29.3% to ₩26.2B despite a 4.7% revenue decline.215200
Q1 202512 Feb 2026 - Strong asset base and net income, with growth driven by education and edtech expansion.215200
Q4 202412 Feb 2026 - H1 2025 revenue fell 5.4% YoY to ₩438.7B; net income was ₩46.6B amid major business restructuring.215200
Q2 202512 Feb 2026 - Revenue and profit declined, but strategic mergers and digital investments support future growth.215200
Q3 202412 Feb 2026 - Revenue and profit fell, but strategic mergers and tech investment support future growth.215200
Q2 202412 Feb 2026 - Revenue down, net income and EPS up; major restructuring and strong shareholder returns.215200
Q3 202512 Feb 2026